Ratio Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Ratio Therapeutics's estimated annual revenue is currently $3.8M per year.
- Ratio Therapeutics's estimated revenue per employee is $100,500
- Ratio Therapeutics's total funding is $90M.
Employee Data
- Ratio Therapeutics has 38 Employees.
- Ratio Therapeutics grew their employee count by 58% last year.
Ratio Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chairman, CEO | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | Chief Legal Officer & General Counsel | Reveal Email/Phone |
4 | Chief Data Officer | Reveal Email/Phone |
5 | Director, President, Chief Scientific Officer | Reveal Email/Phone |
6 | Chief Technology Officer | Reveal Email/Phone |
7 | Chief Operating Officer | Reveal Email/Phone |
8 | Head Biology | Reveal Email/Phone |
9 | Head Discovery | Reveal Email/Phone |
10 | VP, Translational Pharmacology | Reveal Email/Phone |
Ratio Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Ratio Therapeutics?
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie \theranostics\. The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
keywords:N/A
$90M
Total Funding
38
Number of Employees
$3.8M
Revenue (est)
58%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.4M | 38 | N/A | N/A |
#2 | $7.1M | 38 | -14% | N/A |
#3 | $6.4M | 38 | -17% | N/A |
#4 | $6.2M | 38 | 9% | N/A |
#5 | $6.4M | 38 | 0% | N/A |